Myasthenia

Global Myasthenia Gravis Market 2017-2018 & 2026: Increase in Occurrence of Autoimmune Disorders and Strong Pipeline Propelling Market Growth

Retrieved on: 
Friday, January 18, 2019
Autoimmune diseases, Anatomy, Medicine, Nervous system, Myasthenia gravis, RTT, Myasthenia, Neuromuscular disease, Weakness, Neuromuscular junction, Autoimmunity, Neuromuscular junction disease

The "Myasthenia Gravis - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Myasthenia Gravis - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
  • Increasing health care spending & improving health care infrastructure, increase in occurrence of autoimmune disorders and strong pipeline in its treatment are some of the key factors propelling the market growth.
  • However, limited availability of FDA approved drugs and costly treatment options are some issues restricting the market growth.
  • Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups.

Global Myasthenia Gravis Market and Competitive Landscape Report 2018 - Pipeline, Epidemiology, Market Valuations, Product Sales, Market Forecast, Product Forecasts, and Market Shares

Retrieved on: 
Friday, October 26, 2018
Neurological disorders, Myasthenia, Weakness, Medicine, Anatomy, Clinical medicine

The "Global Myasthenia Gravis Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Myasthenia Gravis Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering.
  • Global Myasthenia Gravis Market and Competitive Landscape - 2018, provides comprehensive insights into Myasthenia Gravis pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.
  • This study accurately estimates and forecast Myasthenia Gravis market size and drug sales.
  • The research is classified into following sections - Myasthenia Gravis overview with definitions, symptoms, etiology, diagnosis, treatment options; Myasthenia Gravis pipeline insights covering late stage clinical trials pipeline; Myasthenia Gravis prevalence trends by countries; Myasthenia Gravis market size and forecast by countries, market events, trends; product sales and forecast by countries; market shares by countries.

Myasthenia Gravis (MG) Market 2018 - Epidemiology Forecast to 2027: Current Patient Pool and Forecasted Trend for 7 Major Markets

Retrieved on: 
Thursday, September 27, 2018
Autoimmune diseases, Myasthenia gravis, RTT, Myasthenia, MG, Epidemiology, Medicine, Clinical medicine, Health

The "Myasthenia Gravis (MG) - Epidemiology Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Myasthenia Gravis (MG) - Epidemiology Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Myasthenia Gravis (MG) - Epidemiology Forecast to 2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Myasthenia Gravis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
  • The Myasthenia Gravis (MG) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries.
  • The epidemiology data for Myasthenia Gravis are studied through all possible division to give a better understanding about the Disease scenario in 7MM.

Global Myasthenia Gravis (MG) Market Insights, Epidemiology and Market Forecast 2016-2018 & 2027

Retrieved on: 
Wednesday, September 26, 2018
Autoimmune diseases, Myasthenia gravis, RTT, Myasthenia, Medicine, MG, Weakness, Anatomy, Clinical medicine

The "Myasthenia Gravis (MG) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Myasthenia Gravis (MG) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Myasthenia Gravis (MG) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of MG in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
  • The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Myasthenia Gravis (MG) from 2016 to 2027 segmented by seven major markets.
  • The Myasthenia Gravis (MG) market report gives the thorough understanding of the Myasthenia Gravis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.

GT Biopharma's Chairman and Chief Executive Officer Raymond W Urbanski, M.D., Ph.D Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration

Retrieved on: 
Thursday, August 30, 2018
Medicine, Immunology, Oncology, Cancer immunotherapy, Myasthenia gravis, Myasthenia, Natural killer cell, Clinical medicine

Monday was a monumental and reassuring day for those of us involved in the Natural Killer cell (NK) immuno-oncology field.

Key Points: 
  • Monday was a monumental and reassuring day for those of us involved in the Natural Killer cell (NK) immuno-oncology field.
  • However, each of these platforms and individual therapies has their limitations whether they be safety issues, burden on patients, accessibility issues or cost.
  • Fortunately, a few companies, including GT Biopharma, stayed true to the NK cell hypothesis and continued to drive the science behind this concept.
  • GT Biopharma's neurology products currently include PainBrake, as well as treatments for the symptoms of myasthenia gravis, and motion sickness.

GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration

Retrieved on: 
Wednesday, August 29, 2018
Medicine, Immunology, Oncology, Cancer immunotherapy, Myasthenia gravis, Myasthenia, Natural killer cell, Clinical medicine

Monday was a monumental and reassuring day for those of us involved in the Natural Killer cell (NK) immuno-oncology field.

Key Points: 
  • Monday was a monumental and reassuring day for those of us involved in the Natural Killer cell (NK) immuno-oncology field.
  • However, each of these platforms and individual therapies has their limitations whether they be safety issues, burden on patients, accessibility issues or cost.
  • Fortunately, a few companies, including GT Biopharma, stayed true to the NK cell hypothesis and continued to drive the science behind this concept.
  • GT Biopharma's neurology products currently include PainBrake, as well as treatments for the symptoms of myasthenia gravis, and motion sickness.

GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration

Retrieved on: 
Wednesday, August 29, 2018
Medicine, Immunology, Oncology, Cancer immunotherapy, Myasthenia gravis, Myasthenia, Natural killer cell, Clinical medicine

Monday was a monumental and reassuring day for those of us involved in the Natural Killer cell (NK) immuno-oncology field.

Key Points: 
  • Monday was a monumental and reassuring day for those of us involved in the Natural Killer cell (NK) immuno-oncology field.
  • However, each of these platforms and individual therapies has their limitations whether they be safety issues, burden on patients, accessibility issues or cost.
  • Fortunately, a few companies, including GT Biopharma, stayed true to the NK cell hypothesis and continued to drive the science behind this concept.
  • GT Biopharma's neurology products currently include PainBrake, as well as treatments for the symptoms of myasthenia gravis, and motion sickness.

"The Cello Made Me Half but You Made Whole" Short Film "Silent Cello" Will Tell You the Truth

Retrieved on: 
Monday, August 13, 2018
Myasthenia

The award was given for Ruowei Wang exciting Short Film, Silent Cello, which is the best way to salute his first music teacher, Jian Xu.

Key Points: 
  • The award was given for Ruowei Wang exciting Short Film, Silent Cello, which is the best way to salute his first music teacher, Jian Xu.
  • Silent Cello features exceptionalstory lineabout howthe old cellist would make his own choice between his wife and his art career after he was attacked by Myasthenia Gravis.
  • The IndieFEST Film Awardsrecognizes film, television, videography and new media professionals who demonstrate exceptional achievement in craft and creativity, and those who produce standout entertainment or contribute to profound social change.
  • The goal of The IndieFEST Film Awards is to help winners achieve the recognition they deserve."

GT Biopharma Announces Update to OXS-3550 IND Filing, Its Most Advanced Tri-specific Killer Engager

Retrieved on: 
Wednesday, May 16, 2018
Anatomy, Myasthenia gravis, RTT, Weakness, Myasthenia, Medicine, Clinical medicine

GT Biopharma is working in collaboration with the Masonic Cancer Center at the University of Minnesota under a program led by Dr. Jeffrey Miller, Deputy Director.

Key Points: 
  • GT Biopharma is working in collaboration with the Masonic Cancer Center at the University of Minnesota under a program led by Dr. Jeffrey Miller, Deputy Director.
  • Dr. Miller is a recognized leader in the field of Natural Killer ("NK") cell and IL-15 biology and their therapeutic potential.
  • "We look forward to updating our shareholders on our progress throughout 2018 as we continue to execute on our objectives."
  • GT Biopharma's neurology products currently include PainBrake, as well as treatments for the symptoms of myasthenia gravis, and motion sickness.

Former Sucampo Chief Scientific Officer, Dr. Peter Kiener, Joins GT Biopharma's Board of Directors

Retrieved on: 
Tuesday, April 24, 2018
Mallinckrodt, Myasthenia

GT Biopharma Inc. (OTCQB: GTBP and Euronext Paris "GTBP.PA") today announced that Dr. Peter Kiener will join GT Biopharma's Board of Directors, effective immediately.

Key Points: 
  • GT Biopharma Inc. (OTCQB: GTBP and Euronext Paris "GTBP.PA") today announced that Dr. Peter Kiener will join GT Biopharma's Board of Directors, effective immediately.
  • Dr. Peter Kiener has substantial experience in both biologics and immunotherapy, and was most recently the Chief Scientific Officer at Sucampo, which was acquired by Mallinckrodt in February 2018 for approximately $1.2 billion.
  • Dr. Kiener also currently serves as the chairman of board of directors of Cue Biopharma and as a member of board of directors of Tetragenetics.
  • GT Biopharma's neurology products currently include PainBrake, as well as treatments for the symptoms of myasthenia gravis, and motion sickness.